156 related articles for article (PubMed ID: 38380081)
21. Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancer.
Sprooten J; Vankerckhoven A; Vanmeerbeek I; Borras DM; Berckmans Y; Wouters R; Laureano RS; Baert T; Boon L; Landolfo C; Testa AC; Fischerova D; Van Holsbeke C; Bourne T; Chiappa V; Froyman W; Schols D; Agostinis P; Timmerman D; Tejpar S; Vergote I; Coosemans A; Garg AD
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34795003
[TBL] [Abstract][Full Text] [Related]
22. Molecular profiling of mucinous epithelial ovarian cancer by weighted gene co-expression network analysis.
Zhang GH; Chen MM; Kai JY; Ma Q; Zhong AL; Xie SH; Zheng H; Wang YC; Tong Y; Lu RQ; Guo L
Gene; 2019 Aug; 709():56-64. PubMed ID: 31108164
[TBL] [Abstract][Full Text] [Related]
23. Application of Weighted Gene Coexpression Network Analysis to Identify Key Modules and Hub Genes in Systemic Juvenile Idiopathic Arthritis.
Zhou M; Guo R; Wang YF; Yang W; Li R; Lu L
Biomed Res Int; 2021; 2021():9957569. PubMed ID: 34435051
[TBL] [Abstract][Full Text] [Related]
24. [MiR-4772 modulates tumor immune microenvironment by regulating immune- related genes in ovarian cancer].
Zhao A; Su Y; Fu D
Nan Fang Yi Ke Da Xue Xue Bao; 2022 Nov; 42(11):1638-1645. PubMed ID: 36504056
[TBL] [Abstract][Full Text] [Related]
25. Integrated Bioinformatics Analysis of Master Regulators in Anaplastic Thyroid Carcinoma.
Pan Z; Li L; Fang Q; Qian Y; Zhang Y; Zhu J; Ge M; Huang P
Biomed Res Int; 2019; 2019():9734576. PubMed ID: 31183379
[TBL] [Abstract][Full Text] [Related]
26. Epigenetic silencing of CREB3L1 by DNA methylation is associated with high-grade metastatic breast cancers with poor prognosis and is prevalent in triple negative breast cancers.
Ward AK; Mellor P; Smith SE; Kendall S; Just NA; Vizeacoumar FS; Sarker S; Phillips Z; Alvi R; Saxena A; Vizeacoumar FJ; Carlsen SA; Anderson DH
Breast Cancer Res; 2016 Jan; 18(1):12. PubMed ID: 26810754
[TBL] [Abstract][Full Text] [Related]
27. CREB3L1 as a potential biomarker predicting response of triple negative breast cancer to doxorubicin-based chemotherapy.
Denard B; Jiang S; Peng Y; Ye J
BMC Cancer; 2018 Aug; 18(1):813. PubMed ID: 30103710
[TBL] [Abstract][Full Text] [Related]
28. Comprehensive Analysis of Tripterine Anti-Ovarian Cancer Effects Using Weighted Gene Co-Expression Network Analysis and Molecular Docking.
Long X; Liu L; Zhao Q; Xu X; Liu P; Zhang G; Lin J
Med Sci Monit; 2022 Jan; 28():e932139. PubMed ID: 35022380
[TBL] [Abstract][Full Text] [Related]
29. OASIS/CREB3L1 is epigenetically silenced in human bladder cancer facilitating tumor cell spreading and migration in vitro.
Rose M; Schubert C; Dierichs L; Gaisa NT; Heer M; Heidenreich A; Knüchel R; Dahl E
Epigenetics; 2014 Dec; 9(12):1626-40. PubMed ID: 25625847
[TBL] [Abstract][Full Text] [Related]
30. HOXB4 promotes the malignant progression of ovarian cancer via DHDDS.
Li N; Gou JH; Xiong J; You JJ; Li ZY
BMC Cancer; 2020 Mar; 20(1):222. PubMed ID: 32178630
[TBL] [Abstract][Full Text] [Related]
31. A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer.
Wang H; Liu J; Yang J; Wang Z; Zhang Z; Peng J; Wang Y; Hong L
Front Immunol; 2022; 13():943389. PubMed ID: 36003381
[TBL] [Abstract][Full Text] [Related]
32. Exploiting systems biology to investigate the gene modules and drugs in ovarian cancer: A hypothesis based on the weighted gene co-expression network analysis.
Nomiri S; Karami H; Baradaran B; Javadrashid D; Derakhshani A; Nourbakhsh NS; Shadbad MA; Solimando AG; Tabrizi NJ; Brunetti O; Nasseri S; Racanelli V; Safarpour H; Silvestris N
Biomed Pharmacother; 2022 Feb; 146():112537. PubMed ID: 34922114
[TBL] [Abstract][Full Text] [Related]
33. Identification of potential key genes of TGF-beta signaling associated with the immune response and prognosis of ovarian cancer based on bioinformatics analysis.
Zhang X; Han L; Zhang H; Niu Y; Liang R
Heliyon; 2023 Aug; 9(8):e19208. PubMed ID: 37664697
[TBL] [Abstract][Full Text] [Related]
34. Long non-coding RNA MALAT1 regulates ovarian cancer cell proliferation, migration and apoptosis through Wnt/β-catenin signaling pathway.
Guo C; Wang X; Chen LP; Li M; Li M; Hu YH; Ding WH; Wang X
Eur Rev Med Pharmacol Sci; 2018 Jun; 22(12):3703-3712. PubMed ID: 29949143
[TBL] [Abstract][Full Text] [Related]
35. Identification of key biomarkers associated with development and prognosis in patients with ovarian carcinoma: evidence from bioinformatic analysis.
Shen J; Yu S; Sun X; Yin M; Fei J; Zhou J
J Ovarian Res; 2019 Nov; 12(1):110. PubMed ID: 31729978
[TBL] [Abstract][Full Text] [Related]
36. Identification of the deubiquitinase USP28 as a novel molecular therapeutic target of ovarian cancer.
Shen J; Xie M; Xu Y; Qian Q; Qiu T; Shi W; Ren D; Ji J; Huang J
Biochem Biophys Res Commun; 2023 Jan; 638():184-191. PubMed ID: 36462492
[TBL] [Abstract][Full Text] [Related]
37. Multi-omics analysis of the prognosis and therapeutic significance of circadian clock in ovarian cancer.
Zhu J; Zhou Q; Pan M; Zhou C
Gene; 2021 Jul; 788():145644. PubMed ID: 33848579
[TBL] [Abstract][Full Text] [Related]
38. METCAM/MUC18 is a novel tumor and metastasis suppressor for the human ovarian cancer SKOV3 cells.
Wu GJ; Zeng GF
BMC Cancer; 2016 Feb; 16():136. PubMed ID: 26906545
[TBL] [Abstract][Full Text] [Related]
39. Integrated bioinformatics analysis for the screening of hub genes and therapeutic drugs in ovarian cancer.
Yang D; He Y; Wu B; Deng Y; Wang N; Li M; Liu Y
J Ovarian Res; 2020 Jan; 13(1):10. PubMed ID: 31987036
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive analysis of lncRNA-mRNA co-expression patterns identifies immune-associated lncRNA biomarkers in ovarian cancer malignant progression.
Guo Q; Cheng Y; Liang T; He Y; Ren C; Sun L; Zhang G
Sci Rep; 2015 Dec; 5():17683. PubMed ID: 26631459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
